Journal
BMC PULMONARY MEDICINE
Volume 13, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/1471-2466-13-15
Keywords
Adult asthmatic patients; Asthma guidelines; EQ-5D-3L (R); Drugs cost; Economic evaluation
Categories
Funding
- Novartis
- Boehringer Ingelheim
- AstraZeneca
- GlaxoSmithKline
- Boehringher
- Pfizer
- Chiesi
- Merck
- Almirall
- GlaxoSmithKline, Access to Medicines Centre of Excellence, UK
Ask authors/readers for more resources
Background: Current asthma management guidelines are based on the level of asthma control. The impact of asthma control on health care resources and quality of life (QoL) is insufficiently studied. EUCOAST study was designed to describe costs and QoL in adult patients according to level of asthma control in France and Spain. Methods: An observational cost of illness study was conducted simultaneously in both countries among patients age greater or equal to 18 with a diagnosis of asthma for at least 12 months. Patients were recruited prospectively by GPs in 2010 in four waves to avoid a seasonal bias. Health care resources utilization of the three months before the inclusion was collected through physician questionnaires. Asthma control was evaluated using 2009 GINA criteria over a 3-month period. QoL was assessed using EQ-5D-3L (R). Results: 2,671 patients (France: 1,154; Spain: 1,517) were enrolled. Asthma was controlled in 40.6% [95% CI: 37.7% - 43.4%] and 29.9% [95% CI: 27.6% - 32.3%] of French and Spanish patients respectively. For all types of costs, the percentage of patients using health care resources varied significantly according to the level of asthma control. The average cost (euros/3-months/patient) of controlled asthma was (sic)85.4 (SD: 153.5) in France compared with (sic)314.0 (SD: 2,160.4) for partially controlled asthma and (sic)537.9 (SD: 2,355.7) for uncontrolled asthma (p<0.0001). In Spain, the corresponding figures were (sic)152.6 (SD: 162.1), (sic)241.2 (SD: 266.8), and (sic)556.8 (SD: 762.4). EQ-5D-3L (R) score was higher (p<0.0001) in patients with controlled asthma compared to partially controlled and uncontrolled asthma in both countries (respectively 0.88; 0.78; 0.63 in France and 0.89; 0.82; 0.69 in Spain). Conclusions: In both countries, patients presenting with uncontrolled asthma had a significantly higher asthma costs and lower scores of Qol compared to the others.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available